In Impax Laboratories, Inc. v. FTC, which of the following can qualify as a reverse payment when not cash?

In Impax Laboratories, Inc. v. FTC, which of the following can qualify as a reverse payment when not cash?

• A. Cash payment
• B. An exclusive licensing deal with significant value
• C. Discount on consumer drugs
• D. Free promotional campaign

Answer: (B)

In pay-for-delay settlements, a reverse payment is any transfer of value from the brand to the generic aimed at keeping the generic off the market, not limited to cash. Non-cash arrangements can qualify if they represent a substantial economic benefit exchange tied to delaying entry. An exclusive licensing deal with significant value fits this because it transfers substantial value to the generic in return for staying out of the market, effectively acting as a non-cash payment to delay competition. The other options don’t involve a clear, substantial transfer of value to the generic for the purpose of delaying entry: a cash payment is the classic form, but the question focuses on non-cash arrangements; discounts on consumer drugs primarily benefit consumers rather than the generic in exchange for delay; a free promotional campaign could benefit both sides but doesn’t inherently mirror a direct value transfer intended to restrain competition like an exclusive license does.

In pay-for-delay settlements, a reverse payment is any transfer of value from the brand to the generic aimed at keeping the generic off the market, not limited to cash. Non-cash arrangements can qualify if they represent a substantial economic benefit exchange tied to delaying entry. An exclusive licensing deal with significant value fits this because it transfers substantial value to the generic in return for staying out of the market, effectively acting as a non-cash payment to delay competition. The other options don’t involve a clear, substantial transfer of value to the generic for the purpose of delaying entry: a cash payment is the classic form, but the question focuses on non-cash arrangements; discounts on consumer drugs primarily benefit consumers rather than the generic in exchange for delay; a free promotional campaign could benefit both sides but doesn’t inherently mirror a direct value transfer intended to restrain competition like an exclusive license does.